Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21881780 | 0.92 | L3MBTL1 (0.50) | L3MBTL1HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL22019682 | 0.85 | MEN1 (0.47) | HPGDMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL21881751 | 0.84 | L3MBTL1 (0.43) | L3MBTL1HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL21636327 | 0.83 | L3MBTL1 (0.66) | L3MBTL1HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL21881893 | 0.83 | L3MBTL1 (0.42) | L3MBTL1HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL24941556 | 0.82 | NR1H4 (0.47) | L3MBTL1HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL22020409 | 0.77 | ESR1 (0.41) | HPGDESR1 | |
| SCHEMBL13454341 | 0.76 | LMNA (0.46) | L3MBTL1HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL25060441 | 0.75 | MEN1 (0.40) | HPGDMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL23576145 | 0.75 | TDP1 (0.44) | L3MBTL1HPGDMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3406599-B1 | ORGANIC ELECTRONIC DEVICE COMPRISING AN ORGANIC SEMICONDUCTOR LAYER | NOVALED GMBH (DE) | 2023-02-22 | — | — | EP | disclosed |
| US-20200161559-A1 | Organic Electronic Device Comprising an Organic Semiconductor Layer | NOVALED GMBH (DE) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200161559-A1 | Organic Electronic Device Comprising an Organic Semiconductor Layer | C1S, YAP1, ESR1 | L3MBTL1 710/4885HPGD 4294/4885MEN1 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.